PROSCAR, NEW DRUG FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT, INTRODUCED AT NATIONAL SATELLITE NEWS CONFERENCE TODAY, 1 P.M.
PROSCAR, NEW DRUG FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT, INTRODUCED AT NATIONAL SATELLITE NEWS CONFERENCE TODAY, 1 P.M. WHAT: A national satellite press conference to report on a new drug to treat symptomatic benign prostate enlargement, a common condition in the majority of men over 50 years of age. WHO: -- Dr. E. Darracott Vaughan, professor of urology, and director of division of urology, Cornell University Medical College. -- Dr. Elizabeth Stoner, executive director of clinical research, Merck Research Laboratories. -- Dr. Edward M. Scolnick, president, Merck Research Laboratories, and senior vice president, Merck & Co., Inc. WHEN: Today (Monday, June 22), 1:00 p.m. WHERE: Jade Room, Waldorf Astoria, 301 Park Ave., New York WHY: Some 10 million American men -- over half of all men over 50 -- suffer some symptoms of benign prostate enlargement, a condition that squeezes the urinary tube, blocking the flow of urine and causing persistent discomfort and distress. In rare cases, it can lead to bladder or kidney damage. And over 400,000 American men a year have symptoms severe enough to require surgery. Yet, it's a condition many men suffer privately out of embarrassment. Proscar is the first of a new class of prescription drugs to treat symptomatic benign prostate enlargement. The drug has been studied in over 1,600 men at 76 medical centers worldwide. It is now being introduced by Merck. Merck scientists and experts in urology will present detailed information about benign prostate enlargement and Proscar. They will also be available for questions and individual interviews. CONTACT: Lee Bergman of Robert Marston and Associates, 212-371-2200, or home, 914-730-2009, for Merck; or Gary Bruell of Merck & Co., 215-661-6681, or home, 215-368-7328. -0- 6/20/92 R (MRK) CO: Merck & Co., Inc. ST: Pennsylvania IN: MTC SU: PDT
GK -- NYSA008R -- 2204 06/22/92 07:45 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 22, 1992|
|Previous Article:||OPTICAL DEVICE ENABLES SOME WITH MACULAR DEGENERATION TO DRIVE|
|Next Article:||BARRY BRINK JOINS COOPERS & LYBRAND AS DIRECTOR OF VALUATION PRACTICE|